31.9 C
Vientiane
Sunday, September 14, 2025
spot_img
Home Blog Page 897

U.S. Immigration Fund Welcomes Kiem Nguyen as Vice President of Business Development, Head of Southeast Asia Market

PALM BEACH, Fla., May 1, 2025 /PRNewswire/ — U.S. Immigration Fund, a leading EB-5 Regional Center operator, is pleased to welcome Kiem Nguyen as Vice President of Business Development, Head of Southeast Asia Market. With over a decade of experience in the EB-5 investment industry, Kiem brings a deep understanding of investor needs and a strategic vision to further expand U.S. Immigration Fund’s presence in Southeast Asia.

Kiem Nguyen joins U.S. Immigration Fund as Vice President of Business Development, Head of Southeast Asia Market
Kiem Nguyen joins U.S. Immigration Fund as Vice President of Business Development, Head of Southeast Asia Market

Born and raised in Vietnam, Kiem moved to the United States as a teenager, where he pursued his education, earning a B.A. in Economics and an MBA in International Business. Having lived and worked in both corporate roles and with the U.S. government, he offers a unique perspective on the immigration and business landscapes in both regions. Over the years, he has successfully guided numerous investors through the EB-5 process, helping families relocate, establish businesses, and build their futures in the U.S.

Kiem’s extensive experience includes living in California, Florida, and North Carolina, giving him firsthand insight into the diverse economic and cultural environments that new immigrants encounter. His expertise allows him to provide valuable guidance to families looking to invest, live, work, and grow businesses in the U.S.

In his new role at U.S. Immigration Fund, Kiem will focus on strengthening relationships with investors and partners across Southeast Asia, ensuring they have access to top-tier EB-5 investment opportunities. He is committed to enhancing education and transparency around the EB-5 program, empowering investors with the knowledge and confidence to make informed decisions about their future.

“I am excited to join U.S. Immigration Fund and work with a team dedicated to excellence in the EB-5 industry,” said Kiem. “For many investors in Southeast Asia, EB-5 is not just about immigration—it’s about securing better opportunities and a brighter future for their children. I look forward to helping families make informed decisions and achieve their long-term goals.”

Ashley Flucas, Chief Strategy Officer & General Counsel of U.S. Immigration Fund, underscores the firm’s commitment to investor support: “Kiem Nguyen brings a wealth of experience and an extensive network in the Southeast Asian market, making him an invaluable addition to our team as Vice President of Business Development, Head of South East Asia. His expertise will allow us to further support investors in navigating the EB-5 program with confidence. We look forward to working alongside Kiem as we continue our mission of providing world-class service and opportunities for those seeking to invest in the United States.”

Since its founding, U.S. Immigration Fund has helped thousands of families navigate the EB-5 process, successfully funding large-scale real estate projects with billions in investment capital. With Kiem’s leadership, U.S. Immigration Fund will continue expanding its global reach, providing exceptional service and investment opportunities to families in Southeast Asia seeking U.S. residency.

For more information or to schedule a consultation with Kiem Nguyen, use the links below.

Book a Consultation with Kiem

Visit our website

 

A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis

SUZHOU, China, May 1, 2025 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody KN026 (Study ID: KN026-001) in combination with chemotherapy as second-line or above treatment of HER2-positive gastric cancer (GC) (including gastroesophageal junction cancer (GEJ)), has completed the first interim analysis and met the pre-specified primary endpoint of progression-free survival (PFS) as evaluated by an Independent Data Monitoring Committee (IDMC), with both statistical significance and clinical relevance.

KN026-001 is a randomized, multicenter, Phase II/III clinical study designed to evaluate the efficacy of KN026 in combination with chemotherapy inpatients with HER2-positive advanced, unresectable, or metastatic GC (including GEJ) who have failed first-line treatment. Part 2 of KN026-001 is a randomized, double-blind, placebo-controlled Phase III study. Patients with HER2-positive GC (including GEJ) who had previously received and failed at least first line standard treatment were enrolled and randomized 1: 1 to receive either KN026 in combination with chemotherapy or placebo in combination with chemotherapy. The primary endpoints of this study are PFS and overall survival (OS) as assessed by the Independent Review Committee (IRC).

The interim PFS analysis results demonstrated that, compared to the current standard treatment, KN026 in combination with chemotherapy significantly improved PFS, reduced the risk of disease progression or death, and showed a trend toward OS benefit. Detailed data from this study will be presented at an upcoming international academic conference.

About KN026

KN026 is an anti-HER2 bispecific antibody independently developed by Alphamab Oncology using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific). KN026 can simultaneously bind two non-overlapping epitopes of HER2, leading to HER2 signal blockade. KN026 has demonstrated better tumor inhibition in HER2-positive tumor cell lines compared with trastuzumab and pertuzumab in combination. Additionally, KN026 has also shown inhibitory effect on tumor cells with trastuzumab-resistant cell lines.

The results of multiple clinical studies in different stages showed that KN026 has significant anti-tumor activities, even in heavily pretreated patients with HER2-positive breast cancer (BC) and gastric cancer (GC), including those with prior anti-HER2 treatment. Currently, several pivotal clinical trials of KN026 for the second-line and beyond treatment of HER2-positive GC/gastroesophageal junction cancer (GEJ), the first-line treatment of HER2-positive BC, neoadjuvant treatment for HER2-positive BC are being conducted. KN026 in combination with chemotherapy for the treatment of patients with HER2-positive GC (including GEJ) who have failed first-line standard treatment was granted breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA).

In August 2021, the Company entered an agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK), for the development and commercialization of KN026 in Mainland China, pursuant to which, JMT-Bio was granted exclusive license rights of KN026 for the development and commercialization in the indications of BC an GC/GEJ in Mainland China (excluding Hong Kong, Macau and Taiwan).

About Alphamab Oncology

Alphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a differentiated and globally competitive product portfolio, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies.

The Company has one product approved for marketing (Envafolimab, the world’s first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs to benefit patients.

Canadian Solar Files Annual Report on Form 20-F for Year Ended December 31, 2024

KITCHENER, ON, May 1, 2025 /PRNewswire/ — Canadian Solar Inc. (the “Company”, or “Canadian Solar”) (NASDAQ: CSIQ), today announced the filing of its annual report on Form 20-F for the year ended on December 31, 2024 with the U.S. Securities and Exchange Commission (“SEC”). The annual report on Form 20-F can be accessed on the Company’s Investor Relations website at www.canadiansolar.com or on the SEC’s website at www.sec.gov.

About Canadian Solar

Canadian Solar is one of the world’s largest solar technology and renewable energy companies. Founded in 2001 and headquartered in Kitchener, Ontario, the Company is a leading manufacturer of solar photovoltaic modules; provider of solar energy and battery energy storage solutions; and developer, owner, and operator of utility-scale solar power and battery energy storage projects. Over the past 24 years, Canadian Solar has successfully delivered nearly 150 GW of premium-quality, solar photovoltaic modules to customers across the world. Through its subsidiary e-STORAGE, Canadian Solar has shipped over 10 GWh of battery energy storage solutions to global markets as of December 31, 2024, boasting a US$3.2 billion contracted backlog as of December 31, 2024. Since entering the project development business in 2010, Canadian Solar has developed, built, and connected approximately 11.5 GWp of solar power projects and 4.5 GWh of battery energy storage projects globally. Its geographically diversified project development pipeline includes 25 GWp of solar and 75 GWh of battery energy storage capacity in various stages of development. Canadian Solar is one of the most bankable companies in the solar and renewable energy industry, having been publicly listed on the NASDAQ since 2006. For additional information about the Company, follow Canadian Solar on LinkedIn or visit www.canadiansolar.com.

Canadian Solar Inc. Investor Relations Contact

Wina Huang
Investor Relations
Canadian Solar Inc.
investor@canadiansolar.com 

U.S. Immigration Fund Welcomes Benny Chang as Director of Business Development, Taiwan

PALM BEACH, Fla., May 1, 2025 /PRNewswire/ — U.S. Immigration Fund (USIF), a leading EB-5 Regional Center operator, is pleased to welcome Huaiyang “Benny” Chang as Director of Business Development, Taiwan. With extensive experience in international finance, investment, and global asset allocation strategies, Chang is poised to strengthen USIF’s presence in the Taiwanese market and beyond.

Benny Chang joins U.S. Immigration Fund as Director of Business Development, Taiwan
Benny Chang joins U.S. Immigration Fund as Director of Business Development, Taiwan

Chang began his career managing investment projects at a family office in Singapore, where he developed deep expertise in finance and investment. Since 2018, he has specialized in immigration and overseas real estate investment, advising investors on strategic asset allocation to achieve their financial and residency goals. His profound understanding of investor needs and the Taiwanese market makes him an invaluable addition to USIF’s global business development team.

“I am honored to join USIF, a globally recognized leader in the EB-5 industry,” said Chang. “I look forward to working alongside a world-class team to expand USIF’s reach and provide investors with premier EB-5 opportunities. Collaboration and trust are essential in this industry, and I am eager to build strong relationships with investors and partners worldwide.”

“We are pleased to have Benny Chang join our team,” says Ashley Flucas, Chief Strategy Officer & General Counsel of U.S. Immigration Fund. “His expertise in international investment and deep understanding of the Taiwanese market will help us better serve investors seeking U.S. residency. Benny’s appointment reflects our commitment to expanding USIF’s reach and ensuring our investors have access to the best opportunities available.”

Since its founding, USIF has helped thousands of families secure U.S. residency through EB-5 investments, successfully funding large-scale real estate projects with billions in capital. With Chang’s expertise in business development and investor relations, USIF aims to enhance its service offerings and expand its presence in Taiwan and other key global markets.

For more information or to schedule a consultation with Benny Chang, use the links below.

Book a Consultation with Benny

Visit our website

 

LG Display Becomes World’s First to Verify Commercialization of Blue Phosphorescent OLED Panels

Final Step to Achieving “Dream OLED”

SEOUL, South Korea, May 1, 2025 /PRNewswire/ — LG Display, the world’s leading innovator of display technologies, announced today that it has become the world’s first company to successfully verify the commercialization-level performance of blue phosphorescent OLED panels on a mass production line. The achievement comes about eight months after the company partnered with UDC to develop blue phosphorescence, and is considered a significant step closer to realizing a “dream OLED” display.

LG Display Becomes World's First to Verify Commercialization of Blue Phosphorescent OLED Panels
LG Display Becomes World’s First to Verify Commercialization of Blue Phosphorescent OLED Panels

In the display industry, “dream OLED” refers to an OLED panel that achieves phosphorescence for all three primary colors of light (red, green, and blue). OLED panel light emission methods are broadly categorized into fluorescence and phosphorescence. Fluorescence is a simpler process in which materials emit light immediately upon receiving electrical energy, but its luminous efficiency is only 25%. In contrast, phosphorescence briefly stores received electrical energy before emitting light. Although it is technically more complex, this method offers luminous efficiency of 100% and uses a quarter as much power as fluorescence.

However, achieving blue phosphorescence has remained a major challenge even more than 20 years after the commercialization of red and green phosphorescence. This is due to blue, among the three primary colors, having the shortest wavelength and demanding the greatest energy.

LG Display has solved this issue by using a hybrid two-stack Tandem OLED structure, with blue fluorescence in the lower stack and blue phosphorescence in the upper stack. By combining the stability of fluorescence with the lower power consumption of phosphorescence, it consumes about 15% less power while maintaining a similar level of stability to existing OLED panels.

In particular, LG Display is the first to succeed in reaching the commercialization stage of blue phosphorescent OLED panels, where performance evaluation, optical characteristics, and processability on actual mass production lines should all be confirmed. The company has already completed commercialization verification with UDC.

LG Display has independently filed patents for its hybrid blue phosphorescent OLED technology in both South Korea and the United States.

The company will showcase a blue phosphorescent OLED panel featuring two-stack Tandem technology at SID Display Week 2025, the world’s largest display event, in San Jose, California from May 11th (local time).

At the show, LG Display will be unveiling a blue phosphorescent OLED panel featuring two-stack Tandem technology applied to a small and medium-sized panel that can be applied to IT devices such as smartphones and tablets. As more and more products require high definition and high efficiency such as AI PCs and AR/VR devices, the application of blue phosphorescence technology is expected to expand rapidly.

“The successful commercialization of blue phosphorescence technology, which has been called the final piece of the ‘dream OLED’ puzzle, will become an innovative milestone towards the next generation of OLED,” said Soo-young Yoon, CTO and Executive Vice President of LG Display. “We expect to secure a leading position in the future display market through blue phosphorescence technology.”

About LG Display

LG Display Co., Ltd. [NYSE: LPL, KRX: 034220] is the world’s leading innovator of display technologies, including thin-film transistor liquid crystal and OLED displays. The company manufactures display panels in a broad range of sizes and specifications primarily for use in TVs, notebook computers, desktop monitors, automobiles, and various other applications, including tablets and mobile devices. LG Display currently operates manufacturing facilities in Korea and China, and back-end assembly facilities in Korea, China, and Vietnam. The company has approximately 70,707 employees operating worldwide. For more news and information about LG Display, please visit www.lgdisplay.com.

Media Contact:
Joo Yeon Jennifer Ha, Manager, Communication Team
Email: hjy05@lgdisplay.com

Preserving fertility and optimising care for the one in seven women suffering from endometriosis

SINGAPORE, May 1, 2025 /PRNewswire/ — Fertility specialists in the Asia Pacific region are bringing to fruition new standards of care for women and girls suffering from endometriosis and to help preserve the fertility of those with the debilitating condition.

They have finalised a rigorous consensus process to create a defined and auditable standard for networks of expertise for endometriosis treatment for the one in seven females of reproductive age living with the chronic pelvic pain and fertility risk from the disease.

It sets a gold standard of patient-centred care for sufferers of endometriosis and a similar condition called adenomyosis while considering the diversity of countries, economies, cultures and societies in the APAC region.

The experiences and views of patients living with endometriosis and adenomyosis have been incorporated in developing the consensus structure.

Endometriosis occurs when tissue similar to the inner lining of the uterus grows outside the uterus. It often affects the ovaries, fallopian tubes and the tissue lining the pelvis. Currently, there is no absolute preventive strategy or cure for the condition, but treatment options can help manage its chronic impacts.

The new approaches to endometriosis treatment will be outlined this week at the 2025 Congress of the Asia Pacific Initiative on Reproduction (ASPIRE) in Singapore.

The Congress from today (1 May) to Sunday has brought together over 2,000 scientists, clinicians, nurses and counsellors for a program that will help shape the future of fertility health care in the region and around the world.

New Zealand fertility specialist Professor Neil Johnson, an ASPIRE Board member and Past President of the World Endometriosis Society, has led the endometriosis consensus program with international specialists in the field.

“The topics covered and the way that they have been addressed set new world standards in care, and our hope is that they will influence policy makers and those responsible for health funding decisions,” Professor Johnson explained. 

“My aspiration for the networks of expertise consensus is that it presents what our APAC experts believe to be the optimal model of how complex multidisciplinary care in endometriosis should be best structured. 

“Currently, there is a wide variation in the quality of multidisciplinary care for endometriosis. In many settings, care is provided without the key structures and enmeshment that is crucial for coordinated patient care. 

“This consensus has the potential to become an accreditation gold standard.  It may then be possible to assess the calibre of endometriosis care services across APAC to determine whether they meet the ASPIRE standard to be defined as a network of expertise.

“The consensus on fertility preservation in endometriosis is an issue that has come into sharp focus. In the past, repeated ovarian surgery for endometriosis sufferers has meant that some patients have ended up with extremely low ovarian reserve, which refers to the quantity of eggs remaining in the ovaries with egg quality often negatively affected by endometriosis.

“In some cases, ovarian reserve has become so low that it is very difficult for these patients to achieve a pregnancy either through natural conception or medically assisted reproduction. This is a tragic outcome for young women.

“Our consensus emphasises the need for awareness that endometriosis itself can compromise ovarian reserve along with the impact of ovarian surgery. 

“It highlights the importance of blood testing for anti-mullerian hormone (AMH) levels and ovarian ultrasound for antral follicle count to accurately measure a patient’s ovarian reserve.

“Timing of pregnancy is another important consideration. While it is a personal choice, the ability to conceive may be affected by a decision to delay attempts to become pregnant.

“Of prime importance is the provision of information on fertility preservation to endometriosis sufferers no later than in their twenties. This is vital for patients with severe (stage IV) endometriosis or those facing ovarian surgery. 

“Fertility preservation is typically through egg freezing, although embryo freezing might be preferred by some couples in committed relationships.

“Ovarian tissue freezing may be considered in exceptional cases for endometriosis. Typically, this is an option for cancer patients facing potentially sterilising chemotherapy in the oncology setting. However, more research is needed to explore the role of ovarian tissue freezing for those with endometriosis.   

“Finally, our consensus teams highlight the importance of integrating psychological support and overall fertility counselling as a critical aspect of care.

The ASPIRE 2025 Congress is being held at the Suntec Convention and Exhibition Centre in Singapore. For further information, go to www.ASPIRE2025.com

INTERVIEW: Professor Neil Johnson is available for interview.
To arrange, please contact Trevor Gill, ASPIRE Congress Media Relations
Telephone +61 418 821948 or email lighthousepr@adelaide.on.net 

Rediscovering Quality Home Life Through Nature-Inspired Design at 137th Canton Fair

GUANGZHOU, China, May 1, 2025 /PRNewswire/ — In the fast-paced rhythm of modern urban life, a home has evolved beyond being merely a place to rest, it has become a sanctuary for emotional recharge. While smart technologies continue to redefine convenience and efficiency in household living, another facet of quality home life is quietly gaining momentum: the emotional resonance of nature and simplicity. This alternative vision comes to life at Phase 2 of the 137th China Import and Export Fair (Canton Fair), offering a refreshing interpretation of lifestyle aesthetics grounded in nature.

The Warmth of Wood: Where History Meets the Modern Home

The booth of Shanghai Dandou Home Furnishing Co., Ltd. exudes the rich texture and warmth of aged timber. Specializing in home furniture and decoration, Dandou embraces a philosophy of revitalizing recycled wood, utilizing wood salvaged from historic European and Chinese structures to produce handcrafted and vintage-style furniture.

“The texture on the furniture exhibited here isn’t artificial aging. It’s naturally aged,” explained Shirley Wu, a representative of Dandou. Each piece bears the imprint of decades of exposure to the elements, creating a narrative in every grain. Committed to sustainability, Dandou creatively repurposes off-cuts and scrap pieces into decorative items, extending the material’s lifecycle and embodying a zero-waste philosophy.

Studies have shown that wood surfaces can reduce stress and contribute to a calming environment. Dandou’s seamless integration of these elements into furniture design brings nature indoors, enhancing everyday spaces with quiet elegance and emotional warmth.

Simplicity and Lightness: A Natural Philosophy in Ceramics

This emotional affinity for nature extends into everyday rituals, such as choosing a bowl or cup. Chaozhou Yongxuan Domestic Ceramics Manufactory Co., Ltd. captures this sentiment with a collection that responds to growing consumer interest in tactile, minimalist aesthetics.

“The concept of the collection is ‘returning to nature,'” said Vanessa Xu, the Sales Director of Yongxuan. The design leans toward simplicity but is adapted for modern functionality. Departing from the traditional perception of handmade ceramics as heavy and bulky, Yongxuan applies refined techniques to achieve thinner, lighter forms while preserving artisanal character.

Displayed items, such as cups, plates, bowls, and spoons, feature earthy glazes and textures that suggest a direct link to clay and soil, evoking a sense of grounded beauty. These pieces offer more than utility; they elevate the dining experience into a sensory moment of calm and mindful intention.

A Return to Emotional Value in Home Living

Whether through the storied grains of recycled wood or the grounded textures of handmade ceramics, these products on display at Phase 2 of the 137th Canton Fair reflect a new dimension of quality home life, where nature, emotion, and design converge. In an era of rapidly advancing technology, a home is no longer just a place to keep furniture, it is a space for memory, comfort, and self-expression, while these thoughtful, tactile creations invite a slower, more mindful way of living.

 

 

S&E bio Receives Korea’s First Approval for Exosome-Based Therapy Clinical Trial

SEOUL, South Korea, May 1, 2025 /PRNewswire/ — S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea’s Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b clinical trial of its investigational stroke therapy, SNE-101. This is the first exosome-based therapy in Korea to enter clinical trials, marking a major milestone in the country’s biopharmaceutical landscape.

S&E bio developed SNE-101 using a proprietary 3D culture system to optimize exosome production from umbilical cord-derived mesenchymal stem cells. The exosomes carry therapeutic microRNAs designed to enhance neuroregeneration.

The approval followed successful resolution of Chemistry, Manufacturing, and Controls (CMC) issues, as well as demonstration of therapeutic efficacy not only in rodent models but also in non-human primates, which better reflect human stroke pathology. Long-term safety was also confirmed.

The Phase 1b trial will evaluate the safety, dose-limiting toxicity, and preliminary efficacy of SNE-101 via intravenous administration. As no approved pharmacological therapies currently exist beyond reperfusion treatments for stroke, SNE-101’s potential neuroregenerative, neuroprotective, and anti-inflammatory effects offer new hope for improving recovery in stroke patients.

Media Contact:

Jae Bok Ban
COO, Business Development Division, S&E bio
jbbanbio@snebio.com